



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Andrew H. Cragg, et al
SERIAL NO.: 09/613,439 CONFIRMATION No.: 1758
FILING DATE: 07/11/00
TITLE: SYSTEM AND METHOD FOR FACILITATING HEMOSTATIS
OF BLOOD VESSEL PUNCTURES WITH ABSORBABLE
SPONGE
EXAMINER: Kidwell, Michele M.
ART UNIT: 3761

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as First Class
Mail in an envelope addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on the date printed below:

Date: 5/10/05 Name: Ruth Rodriguez

Mail Stop: Amendment
COMMISSIONER FOR PATENTS
P.O. Box 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Each item of information listed in the attached FORM PTO-1449, for which a copy of each is attached (unless the blanket waiver referred to below applies), may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR §§ 1.56, 1.97 and 1.98. The Examiner is requested to review, consider and document each such item in the official record of this application.

This Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

I

This statement is filed pursuant to (**CHECK ONE BOX**):

☐

37 C.F.R. § 1.97(b).

This information disclosure statement is filed either:

- (1) within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
- (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application;
- (3) before the mailing date of a first office action on the merits; or
- (4) before the mailing of a first office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114, **whichever event occurs last.**

Accordingly, this information disclosure statement requires no fee and no certification.

☒

37 C.F.R. § 1.97(c).

This information disclosure statement is filed **after** the period specified in 37 C.F.R. § 1.97(b), but **before** the mailing date of any of the following:

- (1) a final action under 37 C.F.R. § 1.113;
- (2) a notice of allowance under 37 C.F.R. § 1.311; or
- (3) an action that otherwise closes prosecution in the application.

Accordingly, this information disclosure statement requires either:

- (1) the fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c); or
- (2) a certification according to 37 C.F.R. § 1.97 (e)(1) or (2).

☐

37 C.F.R. § 1.97(d).

This information disclosure statement is filed **after** the period specified in 37 C.F.R. § 1.97 (c).

Accordingly, this information disclosure statement requires:

- (1) a certification in accordance with 37 C.F.R. § 1.97(e); and
- (2) the fee specified in 37 C.F.R. § 1.17 (p) to consider an information disclosure statement under 37 C.F.R. § 1.97(d).

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. **To the extent required,**

please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II

Fees Due (CHECK ONE BOX):

- ☐ No fee is due.
- ☒ The fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) or 37 C.F.R. § 1.97(d) is enclosed (**\$180**).

III

Certification (CHECK ONE BOX):

- ☒ No certification is necessary.
- ☐ Pursuant to 37 C.F.R. § 1.97(e)(1), the undersigned hereby certifies:
That each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ Pursuant to 37 C.F.R. § 1.97(e)(2), the undersigned hereby certifies:
No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this information disclosure statement.


IV

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Please charge any additional required fee or credit any overpayment to our deposit account number 50-1698.

Respectfully submitted,
THELEN REID & PRIEST LLP

Dated: May 12, 2005


Adrienne Yeung
Reg. No.: 44,000

THELEN REID & PRIEST LLP
P.O. Box 640640
San Jose, CA 95164-0640
(408) 292-5800 direct dial
(408) 287-8040 direct fax

Form PT-1449
(Rev. 2-1992)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
034298-069Serial No.
09/613,439

Information Disclosure Statement by Applicant

Applicant: Cragg et al

(Use several sheets if necessary)

Filed: 7/11/00

Group: 3761

U.S. Patent Documents

Init.	Document No.	Date	Name	Class	Subclass	Date
	2,997,195	05/60	Chuen Yuen Yat			
	3,703,174	11/72	Gordon Smith			
	4,591,094	05/86	Morris			
	4,836,204	06/89	Landymore et al			
	5,049,138	09/91	Chevalier et al			
	5,106,376	04/92	Mononen et al			
	5,160,323,	11/92	Andrew			
	5,222,974	06/93	Kensey et al			
	5,292,309	05/94	Van Tassel et al			
	5,299,581	04/94	Donnell et al			
	5,395,353	05/95	Robert Scribner			
	5,417,699	05/95	Klein et al			
	5,437,292	08/95	Kipshidze et al			
	5,441,517	08/95	Kenesev et al			
	5,522,840	06/96	Milan Krajicek			
	5,554,108	09/96	Browning et al			
	5,601,207	02/97	Joseph Paczonay			
	5,601,603	02/97	Oskar Illi			
	5,624,685	08/97	Takahashi et al			
	5,645,849	07/97	Pruss et al			
	5,827,218	10/98	Nguyen et al			
	5,861,004	01/99	Kensey et al			
	5,868,762	02/99	Cragg et al.			
	6,063,061	05/00	Wallace et al			
	6,063,085	05/00	Tay et al			
	6,071,300	06/00	Brenneman, et al.			
	6,585,680	07/03	Mogens Bugge			
	6,197,327	03/01	Harrison et al			
	6,325,789	12/01	Janzen et al			
	6,547,806	04/03	Ni Ding			

Examiner

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

[illegible]